港股异动|亿胜生物科技午后涨逾5%成功完成滴眼液的第一阶段三期试验
格隆汇7月17日丨亿胜生物科技(1061.HK)午后涨幅扩大,现报7.04港元,涨5.55%,暂成交652万港元,最新总市值40.7亿港元。亿胜上周四(11日)晚间发布公告称,就有关公司全资附属Essex Bio-Investment与Mitotech及俄罗斯Mitotech订立共同开发协议,及含SkQ1的滴眼液于美国药监局第一阶段三期临床试验的临床开发,SkQ1作为其唯一的活性药物成分,将提供为干眼症领域的药品。公告显示,第一阶段三期试验已成功完成。预期第一阶段三期试验的顶线数据及进一步发展最新消息将于7月19日(本周五)或前后公布。公告发布后至今,暂已累涨近9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.